Amantadine therapy in parkinsonism
Pakkenberg, H.
Ugeskrift for Laeger 135(3): 135-136
1973
ISSN/ISBN: 0041-5782 PMID: 4685048 Document Number: 66428
Document emailed within 1 workday
Related Documents
Pennacchietti, M.; Aletto, P.M. 1971: On the action of amantadine in postencephalitic parkinsonism Minerva Medica 62(82): 3960-3962Danielczyk, W.; Korten, J.J. 1971: Action of amantadine HCl alone and in combination with L-dopa on parkinsonism Medizinische Monatsschrift 25(10): 472-479
Ferraris, M. 1971: Psychological status of patients with Parkinsonism during treatment with amantadine hydrochloride and L-Dopa Minerva Medica 62(82): 3971-3973
Danielczyk, W. 1995: Twenty-five years of amantadine therapy in Parkinson's disease Journal of Neural Transmission. Supplementum 46: 399-405
Ambrosetto, C.; Martinelli, P. 1971: Clinical considerations on therapy of parkinsonian syndromes with amantadine and L-Dopa Minerva Medica 62(82): 4017-4019
Silver, D.E.; Sahs, A.L. 1971: Double blind study using amantadine hydrochloride in the therapy of Parkinson's disease Transactions of the American Neurological Association 96: 307-308
Nakamura, H.; Uyama, H.; Enomoto, H.; Kishima, Y.; Yamamoto, M.; Yoshida, K.; Okuda, Y.; Hirotani, T.; Kuroda, T.; Ito, H.; Matsuda, M.; Terabayashi, M.; Noguchi, S. 2003: The combination therapy of interferon and amantadine hydrochloride for patients with chronic hepatitis C Hepato-Gastroenterology 50(49): 222-226
Gospavić, J.; Vidaković, Z. 1974: Effectiveness of a combination therapy in the Parkinson syndrome by amantadine hydrochloride and anticholinergic agents Srpski Arhiv Za Celokupno Lekarstvo 102(6): 447-457
Paal, G. 1973: Therapy of parkinsonism Die Medizinische Welt 24(15): 573-576
Jörg, J. 1975: Therapy of parkinsonism using L-Dopa (Brocadopa) Die Medizinische Welt 26(3): 124-126
Bhaskar, P.A.; Bhaskar, E.A.; Jagannathan, K. 1975: Augmenting procedures during L-dopa therapy for Parkinsonism Journal of the Association of Physicians of India 23(1): 21-27
Ajuriaguerra, J.; Gauthier, G.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.; Tissot, R. 1971: Substitution therapy of parkinsonism. Insufficient results with 3-0-methyldopa La Presse Medicale 79(30): 1396
Marjerrison, G.; Boulton, A.A.; Rajput, A. 1971: Dopa therapy in parkinsonism effects on the EEG and amine metabolism Internationale Zeitschrift für Klinische Pharmakologie Therapie und Toxikologie. International Journal of Clinical Pharmacology Therapy and Toxicology 4(2): 263-266
Stammler, A.; Vielhaber, K. 1972: Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor Fortschritte der Neurologie Psychiatrie und Ihrer Grenzgebiete 40(10): 564-568
Yahr, M.D.; Duvoisin, R.C.; Mendoza, M.R.; Schear, M.J.; Barrett, R.E. 1971: Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486) Transactions of the American Neurological Association 96: 55-58
Keenan, R.E. 1970: The Eaton collaborative study of levodopa therapy in parkinsonism: a summary Neurology 20(12): Suppl: 46-65
Mizoi, Y.; Kaneko, H.; Oharazawa, A.; Kuroiwa, H. 1997: Parkinsonism in a patient receiving interferon alpha therapy for chronic hepatitis C Rinsho Shinkeigaku 37(1): 54-56
Eisenlohr, J.J.; Gehlen, W. 1979: Quantitative measurement of muscle tone in patients with Parkinsonism before and during therapy with madopar Fortschritte der Neurologie Psychiatrie und Ihrer Grenzgebiete 47(7): 331-346
Shoulson, I. 1983: Carbidopa/levodopa therapy of coexistent drug-induced parkinsonism and tardive dyskinesia Advances in Neurology 37: 259-266
Sigwald, J.; Raymondeaud, C.; Piot, C. 1973: Method for appraisal and measurement of extrapyramidal symptoms and signs. Clinical evaluation of Parkinsonism. Value in the evaluation of severeness, in the estimation of the evolutive potential, in the appreciation as strict as possible of the effectiveness of antiparkinson therapy La Semaine des Hopitaux: Organe Fonde Par l'Association d'Enseignement Medical des Hopitaux de Paris 49(10): 693-704